Oppenheimer set a $18.00 price target on Recro Pharma (NASDAQ:REPH) in a research note released on Wednesday morning. The firm currently has a buy rating on the specialty pharmaceutical company’s stock. Oppenheimer also issued estimates for Recro Pharma’s FY2022 earnings at $1.99 EPS.
Other equities research analysts have also recently issued reports about the stock. Berenberg Bank initiated coverage on shares of Recro Pharma in a report on Thursday, April 19th. They set a buy rating for the company. ValuEngine upgraded shares of Recro Pharma from a hold rating to a buy rating in a report on Wednesday, April 18th. BidaskClub upgraded shares of Recro Pharma from a hold rating to a buy rating in a report on Thursday, May 24th. Roth Capital set a $9.00 price target on shares of Recro Pharma and gave the company a buy rating in a report on Saturday, May 26th. Finally, Janney Montgomery Scott decreased their price target on shares of Recro Pharma from $21.00 to $11.00 and set a fair value rating for the company in a report on Thursday, May 24th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $12.63.
REPH stock traded down $0.12 during mid-day trading on Wednesday, reaching $5.89. 127,583 shares of the stock traded hands, compared to its average volume of 120,162. The company has a debt-to-equity ratio of 2.22, a quick ratio of 1.55 and a current ratio of 1.59. Recro Pharma has a 52 week low of $4.78 and a 52 week high of $13.05.
Recro Pharma (NASDAQ:REPH) last released its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.34) by $0.72. Recro Pharma had a negative net margin of 75.19% and a negative return on equity of 144.84%. The company had revenue of $21.74 million during the quarter, compared to analysts’ expectations of $16.81 million. equities analysts anticipate that Recro Pharma will post -2.52 EPS for the current fiscal year.
In other news, major shareholder Healthcare Master Fun Broadfin sold 188,000 shares of the company’s stock in a transaction dated Thursday, May 24th. The shares were sold at an average price of $5.81, for a total transaction of $1,092,280.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 21.60% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. Jump Trading LLC acquired a new position in shares of Recro Pharma during the first quarter valued at about $124,000. Citadel Advisors LLC acquired a new position in shares of Recro Pharma during the first quarter valued at about $126,000. Cubist Systematic Strategies LLC acquired a new position in shares of Recro Pharma during the first quarter valued at about $139,000. Two Sigma Investments LP acquired a new position in shares of Recro Pharma during the fourth quarter valued at about $164,000. Finally, Deutsche Bank AG raised its position in shares of Recro Pharma by 141.6% during the fourth quarter. Deutsche Bank AG now owns 30,446 shares of the specialty pharmaceutical company’s stock valued at $281,000 after buying an additional 17,845 shares during the last quarter. 58.57% of the stock is owned by institutional investors and hedge funds.
Recro Pharma Company Profile
Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.